Show simple item record

dc.rights.licenseAtribución-NoComercial-SinDerivadas 4.0 Internacional
dc.contributor.advisorSarmiento Urbina, Isabel Cristina
dc.contributor.advisorLinares Ballesteros, Adriana
dc.contributor.advisorYunis Hazbun, Luz Karime
dc.contributor.authorMartínez Gutiérrez, Cindy Nathalie
dc.date.accessioned2021-05-13T16:37:46Z
dc.date.available2021-05-13T16:37:46Z
dc.date.issued2021-02-28
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/79516
dc.description.abstractLas deleciones de IZF1 y algunos otros genes se han asociado con mal pronóstico. Este estudio tiene como objetivo describir la frecuencia de deleciones de IKZF1, CDKN2A, CDKN2B, PAX5, RB1, BTG1, ETV6, EBF1, JAK2, P2RY8, CSF2RA, ILR3A en una cohorte de pacientes pediatricos con diagnóstico de LLA-B en un centro de referencia. Las deleciones se evaluaron mediante técnica de MLPA. Se recolectaron pacientes entre 2018-2020, en total 117 pacientes con diagnóstico de LLA-B en la Fundación Hospital Pediátrico La Misericordia
dc.description.abstractDeletions in IKZF1 and other genes have been associated with poor prognosis in pediatric B-cell precursor ALL (BCP-ALL). This study aimed to describe the frequency of IKZF1, CDKN2A, CDKN2B, PAX5, RB1, BTG1, ETV6, EBF1, JAK2, P2RY8, CSF2RA, ILR3A deletions in a cohort of Colombian patients with BCP- ALL. Gene deletions were assessed by multiplex ligation-dependent probe amplification (MLPA), using a commercially available kit (SALSA MLPA P335 ALL-IKZF1 probemix). Between 2018 – 2020, 117 de novo pediatric BCP-ALL patients from Fundación Hospital Pediátrico La Misericordia (Bogotá, Colombia) were enrolled. All the patients were treated according to BFM – ALLIC 2009 protocol.
dc.format.extent1 recurso en línea (30 páginas)
dc.format.mimetypeapplication/pdf
dc.language.isospa
dc.publisherUniversidad Nacional de Colombia
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc610 - Medicina y salud::616 - Enfermedades
dc.titleCaracterización molecular de deleción de IKZF1 y otros genes en niños con Leucemia Linfoblástica Aguda de precursores B
dc.typeTrabajo de grado - Especialidad Médica
authorProfile.contributor.emailcimartinezg@unal.edu.co
dc.type.driverinfo:eu-repo/semantics/masterThesis
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.publisher.programBogotá - Medicina - Especialidad en Oncohematología Pediátrica
dc.description.degreelevelEspecialidades Médicas
dc.description.researchareaOncohematología pediátrica
dc.identifier.instnameUniversidad Nacional de Colombia
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombia
dc.identifier.repourlhttps://repositorio.unal.edu.co/
dc.publisher.facultyFacultad de Medicina
dc.publisher.placeBogotá
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotá
dc.relation.references1. Hunger SP, Mullighan CG. Acute Lymphoblastic Leukemia in Children. N Engl J Med. 2015;373(16):1541-1552. doi:10.1056/NEJMra1400972 2. Acuña L, Sánchez P, Uribe D, Pulido D, Valencia O. Situación Del Cáncer En Colombia 2015.; 2015. Disponible en: https://cuentadealtocosto.org/site/images/Situación del Cancer en Colombia 2015.pdf. 3. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4-12. doi:10.1111/ped.13457 4. Trujillo AM, Linares Ballesteros A, Sarmiento IC. Intensive chemotherapy in children with acute lymphoblastic leukemia. Interim analysis in a referral center in Colombia. Rev la Fac Med. 2016;64(3):417. doi:10.15446/revfacmed.v64n3.53961 5. Inaba H, Mullighan CG. Pediatric acute lymphoblastic leukemia. Haematologica. 2020;105(11):2524-2539. doi:10.3324/haematol.2020.247031 6. Cario G, Leoni V, Conter V, Baruchel A, Schrappe M, Biondi A. BCR-ABL1-like acute lymphoblastic leukemia in childhood and targeted therapy. Haematologica. 2020;105(9):2200-2204. doi:10.3324/haematol.2018.207019 7. Ueno H, Yoshida K, Shiozawa Y, et al. Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv. 2020;4(20):5165-5173. doi:10.1182/BLOODADVANCES.2019001307 8. Guía de Práctica Clínica para la detección oportuna, diagnóstico y seguimiento de leucemia linfoide aguda y leucemia mieloide aguda en niños, niñas y adolescentes. Ministerio de Salud y Protección Social - Colciencias, Instituto de Evaluación Tecnológica en Salud IETS, Cinets Alianza. Abril de 2013 9. Payne KJ, Dovat S. Ikaros and tumor suppression in acute lymphoblastic leukemia. Crit Rev Oncog. 2011;16(1-2):3-12. http://www.ncbi.nlm.nih.gov/pubmed/22150303%0Ahttp://www.pubmedcentral. nih.gov/articlerender.fcgi?artid=PMC3243972. 10. Tran TH, Harris MH, Nguyen J V., et al. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. Blood Adv. 2018;2(5):529-533. doi:10.1182/bloodadvances.2017014704 11. Olsson L, Johansson B. Ikaros and leukaemia. Br J Haematol. 2015;169(4):479-491. doi:10.1111/bjh.13342 12. Marke R, Van Leeuwen FN, Scheijen B. The many faces of IKZF1 in B-cell precursor acute lymphoblastic leukemia. Haematologica. 2018;103(4):565-574. doi:10.3324/haematol.2017.185603 13. Ayón-Pérez MF, Pimentel-Gutiérrez HJ, Durán-Avelar MDJ, et al. IKZF1 Gene Deletion in Pediatric Patients Diagnosed with Acute Lymphoblastic Leukemia in Mexico. Cytogenet Genome Res. 2019. doi:10.1159/000499641 14. Gupta SK, Bakhshi S, Kumar L, Seth R, Kumar R. IKZF1 (IKAROS) deletions in B-ALL 30 and its clinical correlation: A prospective study from a tertiary care centre in Northern India. Leuk Res. 2016;41:7-11. doi:10.1016/j.leukres.2015.07.010 15. Ruiz-Delgado GJ, Cantero-Fortiz Y, León-Peña AA, León-González M, Nuñez-Cortés AK, Ruiz-Argüelles GJ. IKAROS Gene Deleted B-Cell Acute Lymphoblastic Leukemia in Mexican Mestizos: Observations in Seven Patients and a Short Review of the Literature. Rev Invest Clin. 2016;68(4):210-214. 16. Granados-Zamora M, Chaves-Herrera K, Morera-Araya E, et al. IKZF1 deletions as a prognostic factor in costa rican patients with pediatric B-Cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2020;42(6):E401-E406. doi:10.1097/MPH.0000000000001807 17. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018;36(12):1240-1249. doi:10.1200/JCO.2017.74.3617 18. Zaliova M, Stuchly J, Winkowska L, et al. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort. Haematologica. 2019;104(7):1396-1406. doi:10.3324/haematol.2018.204974 19. Boer JM, Van Der Veer A, Rizopoulos D, et al. Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study. Leukemia. 2016;30(1):32-38. doi:10.1038/leu.2015.199 20. Gupta SK, Bakhshi S, Kumar L, Kumar V, Kumar R. Gene copy number alteration profile and its clinical correlation in B cell acute lymphoblastic leukemia. Leukemia and Lymphoma. 2017; 58(2):333-342. 21. Schwab CJ, Chilton L, Morrison H, et al. Genes commonly deleted in childhood B-cell precursor acute lymphoblastic leukemia: Association with cytogenetics and clinical features. Haematologica. 2013;98(7):1081-1088. doi:10.3324/haematol.2013.085175 22. Stanulla M, Cavé H, Moorman A V. IKZF1 deletions in pediatric acute lymphoblastic leukemia: Still a poor prognostic marker? Blood. 2020;135(4):252-260. doi:10.1182/blood.2019000813
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.subject.decsLeucemia-Linfoma Linfoblástico de Células Precursoras
dc.subject.decsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
dc.subject.decsPediatría
dc.subject.decsPediatrics
dc.subject.proposalMLPA
dc.subject.proposalLeucemia linfoblástica aguda
dc.subject.proposalDeleción IKZF1
dc.subject.proposalPediatría
dc.subject.proposalFiladelfia LIKE
dc.subject.proposalacute lymphoblastic leukemia
dc.subject.proposalPhiladephia like
dc.subject.proposalIKZF1 deletions
dc.subject.proposalPediatric leukemia
dc.title.translatedIKZF1 and other genes deletions in patients with pediatric b cell acute lymphoblastic leukemia
dc.type.coarhttp://purl.org/coar/resource_type/c_46ec
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.contentText
dc.type.redcolhttp://purl.org/redcol/resource_type/TM
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2
oaire.fundernameFundación Hospital Pediátrico La Misericordia
authorProfile.contributor.genderFemenino


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 4.0 InternacionalThis work is licensed under a Creative Commons Reconocimiento-NoComercial 4.0.This document has been deposited by the author (s) under the following certificate of deposit